The estimated Net Worth of Mark W Parrish is at least $2.44 Milion dollars as of 3 March 2024. Mr. Parrish owns over 18,855 units of Mylan NV stock worth over $1,924,475 and over the last 21 years he sold MYL stock worth over $0. In addition, he makes $520,006 as Lead Independent Non-Executive Vice Chairman of the Board at Mylan NV.
Sign up
Mr. Parrish MYL stock SEC Form 4 insiders trading
Mark has made over 22 trades of the Mylan NV stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 18,855 units of MYL stock worth $298,852 on 3 March 2024.
The largest trade he's ever made was exercising 20,313 units of Mylan NV stock on 3 March 2023 worth over $321,961. On average, Mark trades about 1,924 units every 45 days since 2003. As of 3 March 2024 he still owns at least 121,418 units of Mylan NV stock.
You can see the complete history of Mr. Parrish stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Parrish biography
Mark W. Parrish serves as Lead Independent Non-Executive Vice Chairman of the Board of the Company. Mr. Parrish has served as the Lead Independent Director and Vice Chairman of Mylan’s Board since August 2017. He served as chief executive officer of TridentUSA Health Services (“TridentUSA”), a provider of mobile X-ray and laboratory services to the long-term care industry, from 2008 to August 2018, and as executive chairman from 2008 to 2013. Since August 2018, he has served as executive chairman of TridentUSA. In February 2019, TridentUSA filed for protection under Chapter 11 of the U.S. Bankruptcy Code and emerged from bankruptcy in September 2019. Since January 2013, Mr. Parrish also has served on the board of directors of Omnicell, Inc. (NASDAQ: OMCL), a company that specializes in healthcare technology, and serves on its Audit and Compensation committees; and since May 2019, he has served on the board of directors, and is the chairman of the Audit Committee, of Comprehensive Pharmacy Services, a private company that specializes in the outsourcing of hospital pharmacies. He served on the board of directors of Silvergate Pharmaceuticals, a private company that develops and commercializes pediatric medications, until June 2019, when it was acquired by CutisPharma, Inc.; and on the board of directors of Golden State Medical Supply, a private company that specializes in meeting unique labeling and sizing needs for its customers and pharmaceutical packaging, serialization and distribution, until August 2019, when it was acquired by Court Square. From 1993 to 2007, Mr. Parrish held management roles of increasing responsibility with Cardinal Health Inc. (NYSE: CAH) (“Cardinal”) and its affiliates, including chief executive officer of healthcare supply chain services for Cardinal from 2006 to 2007.
What is the salary of Mark Parrish?
As the Lead Independent Non-Executive Vice Chairman of the Board of Mylan NV, the total compensation of Mark Parrish at Mylan NV is $520,006. There are 3 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of $18,509,300.
How old is Mark Parrish?
Mark Parrish is 64, he's been the Lead Independent Non-Executive Vice Chairman of the Board of Mylan NV since 2017. There are 5 older and 7 younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.
What's Mark Parrish's mailing address?
Mark's mailing address filed with the SEC is OMNICELL, INC, 4220 NORTH FREEWAY, FORTH WORTH, TX, 76137.
Insiders trading at Mylan NV
Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher a Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.
What does Mylan NV do?
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
What does Mylan NV's logo look like?
Complete history of Mr. Parrish stock trades at Mylan NV, Omnicell, Cardinal Health a Viatris
Mylan NV executives and stock owners
Mylan NV executives and other stock owners filed with the SEC include:
-
Heather Bresch,
Chief Executive Officer, Executive Director -
Rajiv Malik,
President, Executive Director -
Robert Coury,
Executive Chairman of the Board -
Mark Parrish,
Lead Independent Non-Executive Vice Chairman of the Board -
JoEllen Dillon,
Non-Executive Independent Director -
Neil Dimick,
Non-Executive Independent Director -
Melina Higgins,
Non-Executive Independent Director -
Sjoerd Vollebregt,
Non-Executive Independent Director -
Robert Cindrich,
Non-Executive Independent Director -
Harry Korman,
Non-Executive Independent Director -
Randall Vanderveen,
Non-Executive Independent Director -
Pauline van der Meer Mohr,
Non-Executive Independent Director -
Richard Mark,
Non-Executive Independent Director -
Melissa Trombetta,
Head of Global Investor Relations -
Joseph C Md Maroon,
Director -
Rodney L Piatt,
Director -
Paul Campbell,
See Remarks -
Laboratories Abbott Product...,
-
Kenneth Scott Parks,
Chief Financial Officer -
Wendy Cameron,
Director -
Douglas J Leech,
Director -
Daniel Martin Jr Gallagher,
Chief Legal Officer -
Anthony Mauro,
Chief Commercial Officer -
John D Sheehan,
EVP and CFO -
Laboratories Abbott Establi...,
-
Laboratories Laboratoires F...,